QS/1, Veridikal partner for reconciliation programs
SPARTANBURG, S.C. — QS/1, a healthcare automation solutions provider, on Monday announced that it now offers Veridikal Intelligence and Veridikal’s Reconciliation program to the pharmacies it serves. The program includes pre- and post-editing, EDI support, 835 processing, forensic auditing and reconciliation.
This type of program allows pharmacies to eliminate many errors before claims are processed, the company said, which increases payments and accelerates prescription delivery to customers.
“Pre- and post-edits service evaluates prescription claims for omissions, errors and compliance with industry standards and metrics,” said Revonda Spratt, QS/1 VP, operations. “This prevents the pharmacy from submitting a claim the insurance provider would reject due to missing or inaccurate information, and decreases the possibility of paying multiple submission charges on a single prescription.”
The Veridikal business edits program allow for additional analysis of claims before they are sent to a third party, helping to reduce the number of errors before the claim is processed to ensure revenue enhancements while also reducing the amount of time pharmacy employees spend on correcting claims that rejected.
“Business edit training and support are provided to all customers,” said Larry Lane, Veridikal SVP marketing. “The pharmacy staff also has the ability to access Veridikal University’s comprehensive training program designed to meet the staff’s schedule and apply for continuing education.”
FDA approves two new indications for Epaned
DENVER — Silvergate Pharmaceuticals on Monday announced that the Food and Drug Administration approved Epaned (enalapril maleate Powder for oral solution) for the treatment of symptomatic heart failure, as well as the treatment of asymptomatic left ventricular dysfunction. The drug was previously approved to treat high blood pressure in patients older than one month of age.
"Now with three indications, Epaned is available to help more patients who need the proven benefits of enalapril in an FDA-approved powder for oral solution, thereby ensuring that they are receiving a medicine that meets the highest quality standards," said Frank Segrave, president and CEO, Silvergate Pharmaceuticals.
Court rules in favor of Mylan’s generic Precedex
PITTSBURGH — Mylan is now free to resume distribution of its generic Precedex product (dexmedetomidine hydrochloride injection) to customers, effective immediately.
The U.S. District Court for the District of Maryland granted summary judgment in favor of the company, Par Sterile Products, and the Food and Drug Administration. The court also lifted a temporary restraining order related to the generic. The drug received FDA approval in August.
Loading Post Please Wait...